Virchows Archiv

, Volume 467, Issue 1, pp 79–86 | Cite as

A national population-based study provides insight in the origin of malignancies metastatic to the ovary

  • Jolien Bruls
  • Michiel Simons
  • Lucy I. Overbeek
  • Johan Bulten
  • Leon F. Massuger
  • Iris D. Nagtegaal
Open Access
Original Article

Abstract

A significant proportion of ovarian malignancies consists of metastatic tumors, with a wide variety in site of origin. Differentiating between a primary and metastatic malignancy of the ovaries can be difficult and misdiagnosis might have considerable impact on both treatment and prognosis. To further examine the origin of malignancies metastatic to the ovary, we performed a large-scale, nationwide search for ovarian metastases in the Dutch Pathology Registry (PALGA). All pathology reports concerning malignancies metastatic to the ovary and associated primary tumors in the Netherlands between 2000 and 2010 were collected. Age, year of diagnosis, tumor type, location of the primary tumor, and side of the ovarian tumor were extracted from the database. We identified 2312 patients fulfilling our selection criteria. The most common primary malignancy sites were colon (33.2 %), endometrium (17.1 %), breast (14.3 %), appendix (7.3 %), and stomach (4.5 %). The metastases were most frequently bilateral (46.3 %) followed by unilateral metastases in the right (26.7 %) and left ovary (19.8 %), while side was unknown in 7.2 % of cases. Of colorectal carcinomas, only 40.2 % metastasized bilaterally, compared to 63.9 % of breast, 62.9 % of gastric, and 58.9 % of appendix carcinomas. Left-sided colorectal carcinomas most often metastasized to the left ovary (p < 0.0001). We found colon carcinomas to be most frequently responsible for metastases to the ovaries, followed by endometrial and breast carcinomas. Metastases from breast, stomach, and appendix carcinomas were mostly bilateral, whereas metastases from colorectal carcinomas were mostly unilateral. The mechanisms underlying preferred sites for metastasis or side remain unclear.

Keywords

Ovarian cancer Mucinous ovarian carcinoma Metastasis Epidemiology 

Introduction

Malignancies metastatic to the ovary are estimated to account for 5–30 % of all ovarian malignancies [1, 2, 3, 4, 5, 6, 7, 8]. These most commonly originate from the colorectum, followed by endometrium, stomach, appendix, and breast [1, 2, 6, 7, 8, 9]. Differentiating between a primary and metastatic malignancy of the ovaries can be complex as many metastatic carcinomas mimic primary ovarian carcinomas [9]. Mucinous ovarian carcinomas (MOC) are notoriously difficult to distinguish from metastatic adenocarcinomas, and as a consequence, the latter are often misdiagnosed as primary tumors [10, 11, 12, 13]. A small study [11] claimed that as many as 40 out of the 52 MOC turned out to be metastases. However, the exact incidence of metastatic disease within the group of MOC is hard to determine. Algorithms as suggested in previous studies [8, 11] are not sufficient to identify all carcinomas metastatic to the ovary. Overlapping marker patterns between gynecological and gastrointestinal malignancies limit the usefulness of immunohistochemistry [9].

Since the treatment of choice of primary ovarian malignancies is different from that of metastatic disease to the ovary, misdiagnoses may have important consequences. As survival data are mostly based upon series containing a mixture of metastatic carcinomas and MOC, these are most likely biased. Although several studies focused on malignancies metastatic to the ovary, most were based upon small patient populations. Therefore, which malignancies most often metastasize to the ovary and which underlying pathways might be involved remains largely unclear. The purpose of the present large-scale, nationwide study was to gain more insight in primary tumor sites.

Materials and methods

Study population

The nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) codes and saves pathology reports in the Netherlands as of 1971 with nationwide coverage as of 1991 [14]. The search terms “ovary” and “all metastases” were used for the years 2000–2010 to collect all pathology reports concerning malignancies metastatic to the ovary. Conclusions of reports were used for further data analysis. A flow chart of the exclusion process is depicted in Fig. 1.
Fig. 1

Flow chart of exclusion process

For each patient, the following items were collected from the pathology report: age at time of diagnosis of ovarian metastasis, year of histological diagnosis, histological type and location of the primary malignancy, and side of the involved ovary. Survival data were not accessible.

Only metastases of which the primary site had been histologically verified were included, and these were classified per organ. Primary squamous or basal cell carcinomas of the skin were excluded. Cases with diagnoses based upon cytology only were excluded from the study. When a carcinoma was clearly not an ovarian primary but histological evidence identifying the primary site was lacking, it was classified as “primary site unknown.” Malignancies of which the distinction between primary and metastatic could not be made with certainty were labeled as “indeterminate site.” For endometrioid carcinomas, several histological criteria have been proposed to distinguish two synchronous primaries from one tumor being a metastasis from the other, although it is generally accepted that these are not always conclusive and definitive distinction is often not possible [15]. Primary fallopian tube carcinomas were excluded since new insight suggests that these are at least partly precursors of ovarian neoplasms [16]. Carcinomas in the ovary were classified by histological type. Metastatic carcinomas of gastrointestinal tract origin were classified as mucinous carcinoma, unless the pathology report stipulated a different specific histological type. When signet-ring cells were present, the carcinoma was classified as signet-ring cell carcinoma. Carcinomas with more than one histological subtype were classified as mixed. If a colorectal carcinoma was reported to invade the ovary directly, it was excluded since these are considered T4 rather than M1 carcinomas according to the latest TNM classification. Peritoneal lesions composed of abundant extracellular mucin, containing scant simple to focally proliferative mucinous epithelium with little cytologic atypia or mitotic activity, were considered as disseminated peritoneal adenomucinosis (DPAM). Peritoneal lesions composed of more abundant mucinous epithelium with the architectural and cytologic features of carcinoma were considered as peritoneal mucinous carcinomatosis (PMCA). Not all reports mentioned specific criteria or immunohistochemical staining used to reach a final diagnosis. The data used was anonymous. The scientific committee of PALGA approved this study.

Statistical analysis

All analyses were performed using SPSS (Statistical Package for the social science; SPSS Inc, Chicago, Illinois) version 20.0. The chi-square test was used to compare multiple nominal variables. Distribution of median age was compared using a Mann-Whitney U test, and the sign test was used to compare two nominal variables. A p value ≤ 0.05 was considered statistically significant.

Results

Patient characteristics

Our search identified 19,403 pathology reports concerning 9980 patients, of which we included 2312 patients (Fig. 1). Median age of all patients with a malignancy metastatic to the ovary was 59 years (range 15–95). Median age of patients with a primary carcinoma of breast (49.5, p < 0.0001), lung (46, p < 0.0001), stomach (55, p = 0.002), and skin (46.5, p = 0.018) was significantly lower and that of patients with a primary carcinoma of bladder (67, p = 0.021) or endometrium (64, p < 0.0001) significantly higher compared to that of patients with a primary carcinoma from other sites. Further details are listed in Table 1.
Table 1

Primary tumor sites, age, and laterality

Location of primary tumor

Number

Percent

Median age, years (range)

Laterality ovarian tumor

Left (%)

Right (%)

Bilateral (%)

 Upper gastrointestinal tract

Esophagus

8

0.3

66.5 (46–87)

2 (33.3)

2 (33.3)

2 (33.3)

Stomach

103

4.5

55 (17–86)*

14 (14.4)

22 (22.7)

61 (62.9)

Duodenum

3

0.1

61 (53–66)

0 (0)

0 (0)

2 (100)

Pancreas

22

1.0

63.5 (35–77)

1 (4.8)

8 (38.1)

12 (57.1)

Extrahepatic bile duct/gallbladder

14

0.6

63.5 (37–83)

3 (21.4)

1 (7.1)

10 (71.4)

Total

150

6.5

58 (1787)

20 (14.3)

33 (23.6)

87 (62.1)

 Lower gastrointestinal tract

Small intestine

38

1.6

59 (34–83)

6 (16.7)

10 (27.8)

20 (55.6)

Appendix

169

7.3

59 (31–86)

19 (11.7)

48 (29.4)

96 (58.9)

Cecum

141

6.1

62 (26–91)

27 (20.6)

44 (33.6)

60 (45.8)

Colon ascendens

122

5.3

62 (15–89)

28 (24.6)

41 (36.0)

45 (39.5)

Colon transversum

35

1.5

58 (29–81)

2 (6.3)

11 (34.3)

19 (59.4)

Colon descendens

58

2.5

62 (25–84)

15 (28.8)

16 (30.8)

21 (40.4)

Rectosigmoid

357

15.4

59 (26–95)

110 (34.9)

98 (30.5)

109 (34.6)

Colon multilocular

13

0.6

50 (32–80)*

2 (16.7)

1 (8.3)

9 (75.0)

Colona

41

1.8

58 (29–81)

4 (11.4)

9 (25.7)

22 (62.9)

Total

974

42.1

60 (1595)

213 (23.9)

276 (31.0)

401 (45.1)

Breast

330

14.3

49.5 (3186)*

43 (14.5)

64 (21.5)

190 (64.0)

Urological tract

Urachus

1

0.0

44

0 (0)

0 (0)

1 (100)

Kidney

8

0.3

62 (42–88)

2 (28.6)

3 (42.9)

2 (28.6)

Bladder

15

0.6

67 (34–78)*

5 (33.3)

6 (40.0)

4 (26.7)

Total

24

0.9

66 (3488)

7 (30.4)

9 (39.1)

7 (30.4)

Genital tract

Vagina

1

0.0

48

1 (100)

0 (0)

0 (0)

Cervix

26

1.1

53 (36–88)

10 (38.5)

8 (30.8)

8 (30.8)

Endometrium

395

17.1

64 (32–89)*

81 (21.4)

115 (30.3)

183 (48.3)

Total

422

18.2

64 (3289)

92 (22.7)

123 (30.3)

191 (47.0)

Primary site unknown

348

15.1

61 (19–89)

64 (19.3)

89 (26.9)

178 (53.8)

Indeterminate primary site

34

1.5

60.5 (39–80)

8 (25.8)

12 (38.7)

11 (35.5)

Other

Lung

19

0.8

46 (35–64)*

8 (44.4)

7 (38.9)

3 (16.7)

Skin

10

0.4

46.5 (25–76)*

2 (22.2)

5 (55.6)

2 (22.2)

Thyroid

1

0.0

48

0 (0)

0 (0)

1 (100)

Total

30

1.2

46.5 (2576)

10 (35.7)

12 (42.9)

6 (21.4)

Total

2312

100

59 (1595)

457 (19.8 %)

618 (26.7 %)

1071 (46.3 %)

Laterality was unknown in 166 cases (7.2 %)

aExact location of primary tumor in the colon not reported

*p < 0.05 compared with median age of all metastases to ovary tumor

Primary tumor sites

Of the 2312 malignancies metastatic to the ovary, the primary tumor was histologically confirmed in 1930 (83.4 %) cases. The most common primary site was colorectum (n = 767, 33.2 %), followed by endometrium (n = 395, 17.1 %), breast (n = 330, 14.3 %), appendix (n = 169, 7.3 %), and stomach (n = 103, 4.5 %), as depicted in Fig. 2.
Fig. 2

Side per site of origin

In 348 cases (15.1 %), the primary site was unknown, but in 261 (75.0 %) of these, a primary location was suggested in the pathology report. Colorectum (n = 65, 18.7 %) was the most commonly suggested primary site, followed by stomach (n = 33, 9.5 %), upper gastrointestinal tract (gallbladder, pancreas or stomach) (n = 37, 10.7 %), breast (n = 26, 7.5 %), appendix (n = 25, 7.2 %) or other (n = 14, 4.1 %). Gastrointestinal tract without any specification of the location was suggested in 61 cases (17.5 %). In 87 cases (25.0 %), no primary site was suggested.

In 34 cases (1.5 %), the primary site was indeterminate. The remaining malignancies metastatic to the ovary (7.0 %) originated from rare primary sites. Further details on primary sites are listed in Table 1.

Histopathology

Mucinous carcinoma was the most common histological type (n = 1082, 46.7 %), followed by signet-ring cell carcinoma (n = 182, 7.9 %), endometrioid carcinoma (n = 179, 7.7 %), and adenocarcinoma not otherwise specified (n = 108, 4.6 %). Mucinous carcinomas originated in 66.4 % (n = 717) from a colorectal carcinoma (CRC). For signet-ring cell carcinomas, the primary site was most often unknown (n = 60, 33.0 %), followed by stomach (n = 52, 28.6 %), colon (n = 34, 18.8 %), and appendix (16.5 %). Ductal and lobular carcinomas were responsible for respectively 7.1 % (n = 165) and 6.7 % (n = 156) of all metastases to the ovary (Table 2).
Table 2

Cases subdivided according to histology of ovarian tumor

Histological type

Number (%)

Adenocarcinoma

2124 (91.9)

 Mucinousa

1167 (50.5)

 Serous

76 (3.3)

 Endometrioid

179 (7.7)

 Clear cell

35 (1.5)

 Signet-ring cell

182 (7.9)

 Ductal

165 (7.1)

 Lobular

156 (6.7)

 Otherb

164 (7.1)

Sarcomac

68 (2.9)

Neuro-endocrine carcinoma

61 (2.6)

Squamous cell carcinoma

16 (0.7)

Transitional cell carcinoma

12 (0.5)

Melanoma

10 (0.4)

Unknown

21 (0.9)

Total

2312 (100.0 %)

aIncludes 79 DPAM associated lesions

bIncludes adenocarcinoma NOS, mixed, adenosquamous, undifferentiated, hepatoid, tubular, tubulopapillary, and villoglandular adenocarcinomas

cIncludes 25 uterine sarcomas and 43 uterine malignant mesodermal mixed tumors

Tumor side

Of all ovarian tumors, 46.3 % was bilateral, 19.8 % was left sided, and 26.7 % right sided. In 7.2 % of cases, side was unknown. The primary site of bilateral metastases was the colon in 26.6 %, breast in 17.7 %, endometrium in 17.1 %, appendix in 9.0 %, and stomach in 5.7 % of cases while 7.3 % were from a carcinoma in another organ and 16.6 % of unknown primary site. Distribution of primary tumor site was almost the same for metastases to the left and right ovaries as shown in Fig. 2.

Remarkably, only 40.2 % CRC gave rise to bilateral ovarian metastases, compared to 63.9 % of breast, 62.9 % of gastric, and 58.9 % of appendix carcinomas (Fig. 3).
Fig. 3

Uni- and bilaterality of ovarian metastases of most frequent sites of origin

Side of the primary CRC was related to which ovary was affected. Metastases to the left ovary originated more often from carcinomas in the left (descending colon and rectosigmoid) than from those in the right colon (cecum and ascending colon) (69.4 %, p < 0.0001). The difference was not statistically significant for metastases to the right ovary. Carcinomas of the appendix metastasized more often to the right ovary (71.6 %, p = 0.016). For no other organ was a difference in side found.

Discussion

Differentiating between a primary ovarian malignancy and a malignancy metastatic to the ovary is challenging but important for prognosis and therapy. Our findings, on the as yet largest case series of 2312 primary malignancies metastatic to the ovary, are mostly consistent with earlier smaller studies with a majority of cases originating from gastrointestinal primaries (Table 3). Differences in distribution are partly associated with country of origin and partly due to small patient numbers. Endometrioid carcinomas are a particular problem as it might be difficult to distinguish between an ovarian metastasis of a primary in the endometrium and a synchronous primary endometrioid carcinoma in the ovary, as described earlier. Our dataset includes a relatively low number of uterine sarcomas and carcinosarcomas (less than 1 % of all cases) compared to some other studies. It must be noted that in all studies, the most frequent primary sites were consistently the gastrointestinal tract, breast, and endometrium [1, 2, 3, 4, 5, 6, 7, 8].
Table 3

Studies examining frequencies of primary sites in metastases to the ovary

Author

Number

Large intestine (%)

Stomach (%)

Appendix (%)

Breast (%)

Endometrium (%)

Unknown origin (%)

Other (%)

Demopoulos 1987

96

12 (13)

6 (6)

1 (1)

32 (33)

14 (15)

0

31 (32)

Petru 1992a

82

23 (28)

22 (27)

0

28 (34)

0

0

9 (11)

Yada-Hashimoto 2003

64

7 (11)

15 (23)

1 (2)

9 (14)

15 (23)

1 (2)

16 (25)

Moore 2004a

59

19 (32)

4 (7)

12 (20)

5 (9)

0

10 (17)

9 (15)

Yemelyanova 2008b

142

46 (32)

5 (4)

26 (18)

0

0

0

65 (46)

De Waal 2009

116

23 (20)

7 (6)

2 (2)

32 (27)

23 (20)

9 (8)

20 (17)

Kondi-Pafiti 2011

97

15 (15)

24 (25)

3 (3)

15 (15)

22 (23)

0

18 (19)

Bruls 2013

2312

767 (33)

103 (5)

169 (7)

330 (14)

395 (17)

382 (17)

166 (7)

aOnly non-genital primary tumor sites were included

bOnly mucinous tumors were included

The relatively high incidence of metastases from CRC is remarkable. In the Netherlands, breast cancer is the most common type of cancer in women (31 %), whereas colorectal cancer accounts for 13 % [17]. Lung cancer is also fairly common (9 %) but relatively infrequently metastasizes to the ovaries. It is unclear why some primary tumor sites are more likely to metastasize to the ovaries than others.

Spread of appendiceal tumors to the ovaries is a notoriously complex phenomenon [18], which was also reflected in our findings. We found 65 low-grade appendiceal tumors (of which 62 associated with DPAM) and 104 appendiceal carcinomas (of which 24 associated with DPAM). Low-grade appendiceal tumor metastases in the ovaries were mostly also low grade, although some presented in the ovary as a carcinoma. Conversely, some appendiceal carcinomas manifested as DPAM, without ovarian involvement by carcinoma. PMCA was not diagnosed in any case which suggests that peritoneal involvement might have been underreported. However, extensive discussion of appendiceal tumors is beyond the scope of this study.

In our series, metastases from an unknown primary site made up the third largest group, with histological features suggestive of a primary site in 75 % of cases. Although this emphasizes the difficulties in distinguishing metastatic from primary malignancies, it is reasonable to believe that the actual number of cases with an unknown primary site is lower. For some patients, the primary site might have been diagnosed but considering factors such as age, physical condition, or prognosis, histological evidence might not have been sought. Incidentally, even though median age for several primary sites such as breast, lung, skin, endometrial, or bladder was significantly different, the wide range prevents age from being useful as a distinguishing feature.

The most frequently seen histological type of carcinoma was mucinous, originating from CRC in most cases. Primary ductal and lobular breast carcinomas were almost equally prevalent (7.1 and 6.7 % of our cases, respectively), even though lobular carcinomas account for only 5–15 % of all breast carcinomas. The loss of expression of the cell-cell adhesion molecule E-cadherin in lobular carcinomas has been suggested as an explanation for the more frequent spread of lobular carcinomas to the gynecological and gastrointestinal tract [19].

Side of the ovarian tumor (left or right) is a poor predictor of primary site, except for tumors originating from CRC. A left-sided ovarian tumor was more likely to originate from a left-sided CRC. Bilateral involvement of the ovaries occurred in half of the patients and was more common in patients with primary breast, stomach, and appendix carcinomas, whereas CRC more frequently presented with unilateral metastasis to the ovary. Interestingly, Petru et al. [20] found a significantly better 5-year survival rate in patients with unilateral compared to bilateral ovarian involvement. The different patterns of metastasis according to primary site, along with differences in survival, suggest that the metastatic routes followed might not be the same. Chang et al. [21] hypothesized that retrograde lymphatic spread might be responsible for ovarian metastases from gastrointestinal cancer. Our finding that most CRCs tend to metastasize only to the ipsilateral ovary suggests that continuous spread through the peritoneal cavity is involved. How often hematogenous spread is involved is not clear, although the tendency of breast cancer to metastasize to both ovaries supports this route. It is generally accepted that patterns of metastatic spread depend on specific characteristics of tumor cells with metastatic potential as well as the micro-environment of recipient tissue [22, 23, 24]. Between organs, properties of the extracellular matrix and vascular endothelial cells are different in terms of homing ligands and production of regulatory factors [25, 26]. While it is still not fully understood why some tumors preferentially metastasize to particular sites or bilateral rather than unilateral, direct transperitoneal spread is an important mechanism in our case series consisting mostly of primary malignancies in the abdomen or pelvis.

We only included histologically confirmed cases but did not revise histology. As for many cases, the criteria used to conclude that an ovarian malignancy was a metastasis from a primary elsewhere, were not available, these were not taken into consideration. While immunohistochemistry is often inconclusive, PAX-8 might prove useful as a marker relatively specific for mucinous ovarian carcinomas [27, 28]. A limitation of our study is its inclusion of patients from a geographically defined area only and in a specific time frame. However, comprehensive coverage of the whole Dutch population in the PALGA database does provide solid evidence of the site of primary malignancies metastatic to the ovary.

In summary, in our large patient series, colon is the most frequent primary site of a malignancy metastatic to the ovary, followed by endometrium and breast. Metastases from breast, stomach, and appendix carcinomas were mostly bilateral. Colorectal carcinoma metastases were mostly unilateral, with a trend for the side of CRC to correspond to the side of the ovarian metastasis. Mechanisms determining patterns of metastasis are still largely unclear, but our observations suggest that these might be different per primary tumor type.

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    de Waal YR, Thomas CM, Oei AL, Sweep FC, Massuger LF (2009) Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 19:1160–1165. doi: 10.1111/IGC.0b013e3181b33cce PubMedCrossRefGoogle Scholar
  2. 2.
    Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, Dastamani C, Bakalianou K, Liapis A, Hassiakos D, Fotiou S (2011) Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet 284:1283–1288. doi: 10.1007/s00404-011-1847-4 PubMedCrossRefGoogle Scholar
  3. 3.
    Demopoulos RI, Touger L, Dubin N (1987) Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol 6:166–175PubMedCrossRefGoogle Scholar
  4. 4.
    Yada-Hashimoto N, Yamamoto T, Kamiura S, Seino H, Ohira H, Sawai K, Kimura T, Saji F (2003) Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314–317PubMedCrossRefGoogle Scholar
  5. 5.
    Khunamornpong S, Suprasert P, Chiangmai WN, Siriaunkgul S (2006) Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. Int J Gynecol Cancer 16(Suppl 1):132–138. doi: 10.1111/j.1525-1438.2006.00302.x PubMedCrossRefGoogle Scholar
  6. 6.
    Antila R, Jalkanen J, Heikinheimo O (2006) Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol 101:97–101. doi: 10.1016/j.ygyno.2005.09.046 PubMedCrossRefGoogle Scholar
  7. 7.
    Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM (2004) Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 93:87–91. doi: 10.1016/j.ygyno.2003.12.039 PubMedCrossRefGoogle Scholar
  8. 8.
    Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138. doi: 10.1097/PAS.0b013e3180690d2d PubMedCrossRefGoogle Scholar
  9. 9.
    McCluggage WG, Wilkinson N (2005) Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47:231–247. doi: 10.1111/j.1365-2559.2005.02194.x PubMedCrossRefGoogle Scholar
  10. 10.
    Lee KR, Young RH (2003) The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27:281–292PubMedCrossRefGoogle Scholar
  11. 11.
    Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27:985–993PubMedCrossRefGoogle Scholar
  12. 12.
    Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA (2011) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117:554–562. doi: 10.1002/cncr.25460 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24:4–25PubMedGoogle Scholar
  14. 14.
    Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMedGoogle Scholar
  15. 15.
    Ulbright TM, Roth LM (1985) Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 16:28–34PubMedCrossRefGoogle Scholar
  16. 16.
    Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42:918–931. doi: 10.1016/j.humpath.2011.03.003 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cancer Statistics, Dutch Cancer Registry. www.cijfersoverkanker.nl
  18. 18.
    Misdraji J (2010) Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med 134:864–870. doi: 10.1043/1543-2165-134.6.864 PubMedGoogle Scholar
  19. 19.
    Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113–120. doi: 10.1002/(sici)1097-0142(19960101)77:1<113::aid-cncr19>3.0.co;2-8 PubMedCrossRefGoogle Scholar
  20. 20.
    Petru E, Pickel H, Heydarfadai M, Lahousen M, Haas J, Schaider H, Tamussino K (1992) Nongenital cancers metastatic to the ovary. Gynecol Oncol 44:83–86PubMedCrossRefGoogle Scholar
  21. 21.
    Chang TC, Changchien CC, Tseng CW, Lai CH, Tseng CJ, Lin SE, Wang CS, Huang KJ, Chou HH, Ma YY, Hsueh S, Eng HL, Fan HA (1997) Retrograde lymphatic spread: a likely route for metastatic ovarian cancers of gastrointestinal origin. Gynecol Oncol 66:372–377. doi: 10.1006/gyno.1997.4793 PubMedCrossRefGoogle Scholar
  22. 22.
    Mathot L, Stenninger J (2012) Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 103:626–631. doi: 10.1111/j.1349-7006.2011.02195.x PubMedCrossRefGoogle Scholar
  23. 23.
    Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101PubMedGoogle Scholar
  24. 24.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi: 10.1016/j.cell.2011.02.013 PubMedCrossRefGoogle Scholar
  25. 25.
    Langley RR, Fidler IJ (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28:297–321. doi: 10.1210/er.2006-0027 PubMedCrossRefGoogle Scholar
  26. 26.
    Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, Ruegg C (2012) Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol 22:174–186. doi: 10.1016/j.semcancer.2012.02.007 PubMedCrossRefGoogle Scholar
  27. 27.
    Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD (2011) PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol 24:751–764. doi: 10.1038/modpathol.2011.3 PubMedCrossRefGoogle Scholar
  28. 28.
    Ordonez NG (2012) Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol 19:140–151. doi: 10.1097/PAP.0b013e318253465d PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Jolien Bruls
    • 1
  • Michiel Simons
    • 1
  • Lucy I. Overbeek
    • 2
  • Johan Bulten
    • 1
  • Leon F. Massuger
    • 3
  • Iris D. Nagtegaal
    • 1
  1. 1.Department of Pathology 824Radboud university medical centerNijmegenThe Netherlands
  2. 2.PALGA FoundationUtrechtThe Netherlands
  3. 3.Department of Obstetrics and GynecologyRadboud university medical centerNijmegenThe Netherlands

Personalised recommendations